UK markets close in 7 hours 21 minutes
  • FTSE 100

    7,422.99
    +120.25 (+1.65%)
     
  • FTSE 250

    19,993.77
    +304.75 (+1.55%)
     
  • AIM

    958.79
    +11.62 (+1.23%)
     
  • GBP/EUR

    1.1796
    +0.0014 (+0.12%)
     
  • GBP/USD

    1.2462
    -0.0013 (-0.11%)
     
  • BTC-GBP

    24,233.27
    +754.83 (+3.21%)
     
  • CMC Crypto 200

    672.65
    +20.41 (+3.13%)
     
  • S&P 500

    3,900.79
    -22.89 (-0.58%)
     
  • DOW

    31,253.13
    -236.94 (-0.75%)
     
  • CRUDE OIL

    111.65
    -0.56 (-0.50%)
     
  • GOLD FUTURES

    1,842.40
    +1.20 (+0.07%)
     
  • NIKKEI 225

    26,739.03
    +336.19 (+1.27%)
     
  • HANG SENG

    20,773.49
    +652.81 (+3.24%)
     
  • DAX

    14,073.29
    +190.99 (+1.38%)
     
  • CAC 40

    6,336.11
    +63.40 (+1.01%)
     

How Many Biomea Fusion, Inc. (NASDAQ:BMEA) Shares Do Institutions Own?

  • Oops!
    Something went wrong.
    Please try again later.
·5-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The big shareholder groups in Biomea Fusion, Inc. (NASDAQ:BMEA) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Companies that have been privatized tend to have low insider ownership.

Biomea Fusion is a smaller company with a market capitalization of US$409m, so it may still be flying under the radar of many institutional investors. In the chart below, we can see that institutional investors have bought into the company. Let's delve deeper into each type of owner, to discover more about Biomea Fusion.

Check out our latest analysis for Biomea Fusion

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Biomea Fusion?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Biomea Fusion already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Biomea Fusion's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

It looks like hedge funds own 11% of Biomea Fusion shares. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Our data shows that A2A Pharmaceuticals, Inc. is the largest shareholder with 15% of shares outstanding. With 15% and 11% of the shares outstanding respectively, Biomea Health, Llc and Cormorant Asset Management, LLC are the second and third largest shareholders. In addition, we found that Thomas Butler, the CEO has 1.1% of the shares allocated to their name.

Our research also brought to light the fact that roughly 50% of the company is controlled by the top 5 shareholders suggesting that these owners wield significant influence on the business.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Biomea Fusion

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

We can see that insiders own shares in Biomea Fusion, Inc.. In their own names, insiders own US$7.7m worth of stock in the US$409m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public holds a 44% stake in Biomea Fusion. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With an ownership of 7.3%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Private Company Ownership

It seems that Private Companies own 31%, of the Biomea Fusion stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Biomea Fusion better, we need to consider many other factors. To that end, you should learn about the 4 warning signs we've spotted with Biomea Fusion (including 2 which make us uncomfortable) .

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting